Atogepant
Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.It was approved for medical use in the United States in September 2021.

Medical uses
Atogepant is indicated for the preventive treatment of episodic migraine in adults.

Research
A study found that atogepant reduced the number of migraine days over twelve weeks.

References
External links
"Atogepant". Drug Information Portal. U.S. National Library of Medicine.